Compare CXAI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | NRSN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Israel |
| Employees | 35 | 16 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 25.5M |
| IPO Year | N/A | N/A |
| Metric | CXAI | NRSN |
|---|---|---|
| Price | $0.17 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 26.2M | 207.0K |
| Earning Date | 05-19-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.54 | N/A |
| Revenue Next Year | $116.67 | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.63 |
| 52 Week High | $1.15 | $2.19 |
| Indicator | CXAI | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 40.74 |
| Support Level | $0.15 | $0.68 |
| Resistance Level | $0.17 | $0.75 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 5.70 | 13.54 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.